Frequently Asked Questions

Bone marrow transplant (BMT) and cellular therapy involve replacing diseased bone marrow with healthy stem cells to help restore blood production. These life-saving procedures are generally advised for patients with aggressive blood cancers or genetic disorders. With the guidance of Dr. Nivedita Dhingra, Director & Head - Hematology, Hemato-Oncology and Bone Marrow Transplant, Yashoda Medicity, these therapies offer a treatment pathway for diseases that no longer respond to conventional treatments.

Advanced haematology and haemato-oncology care represent advanced medical care for blood-related disorders and cancers. It focuses on identifying and treating complex blood disorders and malignancies using the latest diagnostic tools, targeted therapies, immunotherapy, and stem cell transplantation techniques.

CAR-T cell therapy uses the patient’s own immune system to fight cancer by genetically modifying T cells to specifically target cancer cells. This "living drug" has shown remarkable promise in helping patients with B-cell lymphomas and leukaemias that are resistant or have relapsed after treatment. Dr. Nivedita Dhingra, a specialist in innovative immunotherapies, provides this advanced cellular therapy to patients who may no longer respond to standard treatments.

Sickle Cell Disease is a genetic blood disorder that affects the shape and function of red blood cells. Sickle Cell Disease and Thalassemia are common inherited haemoglobin disorders that can cause chronic anaemia, while immune deficiencies and metabolic disorders affect the body’s immune function and metabolic processes. These conditions often require specialised long-term hematology care and monitoring.

BMT and cellular therapies are important treatment options for several disorders, including leukaemia, lymphoma, and multiple myeloma. They are also used for non-malignant but serious conditions such as Thalassemia, Sickle Cell Disease, and severe aplastic anaemia. Dr. Nivedita Dhingra’s expertise includes autologous and allogeneic stem cell transplantation, including complex haplo-identical and unrelated donor transplants.

A bone marrow transplant is generally recommended when these cancers are high-risk, have relapsed, or do not respond adequately to chemotherapy. Autologous transplant is often considered the standard treatment approach for multiple myeloma, whereas an allogeneic transplant may be recommended in certain cases of leukaemia and lymphoma to replace diseased bone marrow with healthy donor cells.

Cellular therapy, especially CAR-T cell therapy, has transformed the treatment of resistant blood cancers. It works by reprogramming the patient’s immune cells to recognize and attack cancer cells more effectively. These advanced therapies can help achieve remission even in difficult-to-treat or relapsed cases.

Treatment may involve a combination of high-dose chemotherapy, targeted therapy, immunotherapy, and advanced supportive care. In more complex cases, stem cell transplantation may be used to restore healthy bone marrow after eliminating diseased cells. Treatment plans are carefully personalised according to the type and stage of cancer.

Under advanced hematology care, treatment options include blood transfusions, iron chelation therapy, supportive medications, and curative bone marrow transplant. For patients with Thalassemia or Sickle Cell Disease, Dr. Nivedita Dhingra also offers advanced transplant options such as haplo-identical transplantation, where partially matched family donors may be considered for treatment.

Patients should consult a highly trained BMT Specialist and Hematologist who is experienced in managing complex transplant procedures and advanced cellular therapies such as CAR-T therapy. These specialists are capable of leading multidisciplinary transplant teams while ensuring safe and evidence-based patient care throughout the treatment process.

Dr. Nivedita Dhingra manages complex cases through a detailed and patient-focused approach. Her area of specialization includes Alternative Donor Transplants, where unrelated or half-matched (haplo-identical) donors are used when a fully matched sibling donor is unavailable. With expertise in cellular therapies, pediatric and adult hematology care, and advanced transplant medicine, she has successfully managed challenging hematologic malignancies and immune deficiency disorders.

Patients in Delhi NCR and Ghaziabad can access advanced BMT and cellular therapy services under the leadership of Dr. Nivedita Dhingra. The facility offers specialised transplant units, advanced hematology infrastructure, and comprehensive supportive care, allowing patients to receive advanced transplant and cellular therapy treatment closer to home.

Yes, Yashoda Medicity, Ghaziabad, is equipped with state-of-the-art facilities to provide advanced bone marrow transplant and CAR-T cell therapy services. Under the leadership of Dr. Nivedita Dhingra, the hematology and hemato-oncology program offers advanced treatment for complex blood disorders through stem cell transplantation, cellular therapies, and modern immune-based treatment approaches.